{"entity":{"id":"nct05952024","kind":"trial","name":"Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL","aka":[],"tldr":"A phase 2 trial of Acalabrutinib, Rituximab in diffuse large b-cell lymphoma, run by AstraZeneca, now recruiting.","summary":"Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL is a phase 2 interventional study registered as NCT05952024 by AstraZeneca, with 80 participants planned, started 2024-07-16 and due to reach its primary completion in 2029-04-22. Interventions recorded: Acalabrutinib, Rituximab. Conditions listed: Diffuse Large B-Cell Lymphoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05952024","url":"https://clinicaltrials.gov/study/NCT05952024"}],"tags":["ctgov-ingest"],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":[],"targets":[],"drugs":["acalabrutinib","rituximab"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05952024","phase":"2","setting":"A Prospective, Open-Label, Single-Arm, Phase II Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With Diffuse Large B-Cell Lymphoma (ACRUE)","sponsor":"AstraZeneca","enrolled":80,"outcomes":[]},"route":"/trials/nct05952024/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"drug":[{"id":"acalabrutinib","kind":"drug","name":"Acalabrutinib","route":"/drugs/acalabrutinib/"},{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}